Therapeutic Strategy Details
| Strategy ID: | S07 |
| Strategy: | antihypertensive |
| Other Terms: | Anti-fibrosis; Anti-hypertensive; Anti-hypertensive; antihypertensive medications; multidrug combination antihypertensive treatment; empirical addition (or increase in the dose) of an antihypertensive agent of a different class""; Anti-hypertensive; Lifestyle measures; Anti-inflammatory; Improve insulin resistance; Enhance lipid metabolism; Regulating intestinal flora; Anti-hypertensive; Anti-hypertensive; Anti-inflammatory; Anti-fibrosis; Anti-inflammatory; Immunotherapy; Anti-hypertensive; Immunosuppressive treatment; Anti-hypertensive; Anti-hypertensive; Anti-platelet aggregation; other antihypertensive drugs; antihypertensive therapy; Anti-hypertensive; Anti-inflammatory; Anti-hypertensive (standard antihypertensive treatment; intensive antihypertensive treatment); Blood pressure management; Anti-hypertensive; Enhance lipid metabolism; Anti-hypertensive; Enhance lipid metabolism; Anti-platelet aggregation; Improve insulin resistance; Anti-hypertensive; Anti-hypertensive; Anti-oxidative stress; antihypertensives; Lifestyle measures; Anti-hypertensive; Anti-fibrosis; Anti-inflammatory; Anti-hypertensive |
| Related Targets: | ACE; Smad4; PKD1; angiotensin receptor; SGLT2; angiotensin II receptor; mineralocorticoid receptor; ACE |
| Related Drugs: | riociguat; sGC stimulators; sGC activators; antihypertensive medications; carvedilol; lercanidipine; enalapril; folic acid; retinoic acid; angiotensin II; antihypertensive drug; Tripterygium Wilfordii Hook F; valsartan; Renin-angiotensin system inhibitors; diuretics; calcium channel blocker; corticosteroid; anti-hypertensive treatment; NSAIDs; naproxen; celecoxib; proton pump inhibitor; non-selective NSAID; selective cyclo-oxygenase-2 inhibitor; renin-angiotensin system blockers; antihypertensive agent; cilnidipine; valsartan; RAAS-is; steroids; immunosuppressors; amiloride; hydrochlorothiazide; berberine; Aliskiren; calcium channel blocker; angiotensin II receptor blocker; ARB; Chlorthalidone; Hydrochlorothiazide; Hsub2/subS; NO; Hsub2/subSxa0; xa0; NO; prednisolone; mizoribine; angiotensin-converting enzyme inhibitors; ACEI; eculizumab; antihypertensive agents; antithrombotics; antianemics; proton pump inhibitors; allopurinol; rilmenidine; long-term benzodiazepines; anticholinergic drugs; hydroxyzine; Qian Yang Yu Yin Granule; RAAS blockers; other antihypertensive drugs; antihypertensives; antihypertensive classes; antihypertensive therapy; melatonin; RAASi; Aliskiren; ARBs; ACEIs; tegafur/gimeracil/oteracil; furosemide; prednisolone; angiotensin receptor blockers; valsartan; antihypertensive drugs; fosinopril; valsartan; Canagliflozin; sodium glucose co-transporter 2 inhibitors; Aspirin; Antihypertensive; Lipid-Lowering Treatment; Sodium-glucose cotransporter 2 inhibitors; angiotensin II receptor blocker; Spironolactone; KBP-5074; captopril; enalaprilate; lisinopril; losartan; valsartan; furosemide; pravastatin; simvastatin; Renin Angiotensin System inhibitors; ACE inhibitors; diuretics; β-blockers; Thiazide diuretics; dihydropyridine calcium-channel blockers; angiotensin-converting enzyme inhibitors; angiotensin receptor blockers; calcium-channel blockers; thiazide-like diuretics; lisinopril; Edarbyclor; azilsartan medoxomil; chlorthalidone; hydrochlorothiazide; aliskiren; ARB; enalapril; non-steroidalanti-inflammatory drugs; antihypertensive treatment; Chlorthalidone; loop diuretics; angiotensin-converting enzyme inhibitor; angiotensin receptor blocker; statin; captopril; tiopronin; active form of dalcetrapib; active metabolite of prasugrel, R-138727; Liuwei Dihuang pills; metformin hydrochloride sustained-release tablets; irbesartan tablets; renin-angiotensin-aldosterone system inhibitor; type 1 angiotensin II receptor blockade; olmesartan; steroid; immunosuppressive agents; enalapril; corticosteroid treatment; Angiotensin-converting-enzyme inhibitors; antihypertensives; GLP-1 receptor analogue; SGLT2-inhibitor; sacubitril/valsartan; valsartan; Sulodexide; liraglutide; enalapril; ACE-I/ARBs; angiotensin-converting enzyme inhibitor/angiotensin II receptor blockers; labetalol; ACEi; ARB; ARBs |
| Mechanism: | |
| Reference (PMIDs): | 30689085; 31102525; 31353479; 31629573; 31697927; 31801679; 31816171; 31834125; 31838636; 31875937; 31882172; 31937550; 31964180; 31977575; 31996411; 32005442; 32037898; 32065600; 32068124; 32103732; 32129200; 32131742; 32147479; 32156479; 32169049; 32242852; 32253275; 32303191; 32359350; 32378178; 32410703; 32444456; 32466632; 32470492; 32490642; 32501546; 32506833; 32508195; 32520623; 32545617; 32564693; 32584617; 32592137; 32595000; 32617578; 32624484; 32649633; 32663820; 32682696; 32744915; 32756091; 32762878; 32786093; 32787808; 32794421; 32801242; 32845571; 32845715; 32851094; 32877912; 32901433; 32946852; 32951311; 33031368 |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D023 | Glycine | small molecule | DB00145 | Details | |||
| D024 | Calcifediol | small molecule | DB00146 | Details | |||
| D037 | Pyridoxine | small molecule | DB00165 | Details | |||
| D049 | Fluconazole | small molecule | DB00196 | Details | |||
| D054 | Reserpine | small molecule | DB00206 | Details | |||
| D075 | Pamidronic acid | small molecule | DB00282 | Details | |||
| D083 | Valproic acid | small molecule | DB00313 | Details | |||
| D084 | Acetaminophen | small molecule | DB00316 | Details | |||
| D085 | Piperacillin | small molecule | DB00319 | Details | |||
| D089 | Metformin | small molecule | DB00331 | Details |
| Candidate ID | Source ID | Source Type | Compound Type | Candidate Name | Inclusion Criteria | |
|---|---|---|---|---|---|---|
| R0023 | DB00145 | approved; nutraceutical; vet_approved | small molecule | Glycine | Details | |
| R0024 | DB00146 | approved; nutraceutical | small molecule | Calcifediol | Details | |
| R0037 | DB00165 | approved; investigational; nutraceutical; vet_approved | small molecule | Pyridoxine | Details | |
| R0049 | DB00196 | approved; investigational | small molecule | Fluconazole | Details | |
| R0054 | DB00206 | approved; investigational | small molecule | Reserpine | Details | |
| R0075 | DB00282 | approved | small molecule | Pamidronic acid | Details | |
| R0083 | DB00313 | approved; investigational | small molecule | Valproic acid | Details | |
| R0084 | DB00316 | approved | small molecule | Acetaminophen | Details | |
| R0085 | DB00319 | approved | small molecule | Piperacillin | Details | |
| R0089 | DB00331 | approved | small molecule | Metformin | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00139 | 21536946 | Diabetes | Diazoxide-unresponsive congenital hyperinsulinism in children with dominant mutations of the β-cell sulfonylurea receptor SUR1. | Details |
| A00171 | 28838955 | J Am Soc Nephrol | Bosutinib versus Placebo for Autosomal Dominant Polycystic Kidney Disease. | Details |